Editorial Recent evidence on delamanid use for rifampicin-resistant tuberculosis Emanuele Pontali, Rosella Centis, Lia D’Ambrosio, Federica Toscanini, Giovanni Battista Migliori Abstract Delamanid is one of the two most recently approved new anti-tuberculosis (TB) drugs.
